- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT03488602
Focused Suicide Prevention Strategy for Youth (FSPS)
A Focused Suicide Prevention Strategy for Youth Presenting to the Emergency Department With Suicide Related Behaviour: A Randomized Controlled Trial
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This is a RCT of a patient- and family-centered suicide prevention intervention added to usual care (F-SPS + UC) for adolescents aged 12 to 18 years who present to the Emergency Department (ED) with suicidal ideation or suicide risk behaviours. The investigators will determine whether the F-SPS + UC intervention is more effective than enhanced usual care (EUC) in reducing suicide-related behaviors in 128 youth at high-risk of suicide.
F-SPS is a 6-week, standardized, manualized outpatient program that teaches participants to the skills to manage suicidal thoughts and impulses effectively. The family component addresses conflictual relationships that may be present in the family as well as improving family communication.
Enhanced usual care consists of 6 weekly telephone calls to ensure that the participant has connected with community resources suggested by the ED team and provide additional resources as needed.
Tipo de estudo
Inscrição (Antecipado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Matthew Tracey, MA
- Número de telefone: 201575 4165358501
- E-mail: matthew.tracey@sickkids.ca
Estude backup de contato
- Nome: Reva Schachter, MSc
- Número de telefone: 201469 4165358501
- E-mail: reva.schachter@sickkids.ca
Locais de estudo
-
-
Ontario
-
Toronto, Ontario, Canadá, M5G 1X8
- Recrutamento
- Matthew Tracey
-
Subinvestigador:
- Myla Moretti, PhD
-
Contato:
- Matthew Tracey, MA
- Número de telefone: 201575 4165358501
- E-mail: matthew.tracey@sickkids.ca
-
Contato:
- Reva Schachter, MSc
- Número de telefone: 201469 4165358501
- E-mail: reva.schachter@sickkids.ca
-
Investigador principal:
- Daphne J Korczak, MD, Msc
-
Investigador principal:
- Yaron Finkelstein, MD
-
Subinvestigador:
- Melanie Barwick, PhD
-
Subinvestigador:
- Peter Szatmari, MD
-
Subinvestigador:
- Kristin Cleverly, PhD
-
Subinvestigador:
- Gloria Chaim, MSW
-
Subinvestigador:
- Joanna Henderson, PhD
-
Subinvestigador:
- Suneeta Monga, MD
-
Subinvestigador:
- David Juurlink, MD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Ages 12 to18 years
- Youth presenting in the Emergency Department with acute suicidal ideation or suicide risk behaviour
- SIQ-Jr score ≥ 31
- Parent or caregiver able to communicate in English, or is willing to communicate using a hospital-organized translator, and willing to participate in study
- Living in the greater Toronto area and access to a telephone.
Exclusion Criteria:
- Active psychosis or hypomania/mania
- Moderate to severe intellectual disability, autism.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: F-SPS Intervention
This group will receive the F-SPS intervention.
|
Manualized individual and family program. Weekly individual and family sessions with a therapist for 6 weeks. Participants will continue to receive usual care.
Outros nomes:
|
Comparador Ativo: Enhanced Usual Care (EUC)
This group will receive Enhanced Usual Care (EUC)
|
Weekly telephone contact with parents regarding participant health care utilization. Referrals to community mental health resources provided as needed. Participants will continue to receive usual care. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Change in suicidal ideation severity as measured by the Suicidal Ideation Questionnaire - Jr
Prazo: Screening, 6 weeks, 24 weeks
|
a 15-item measure self-report of suicide ideation (e.g., thoughts about death and dying) completed by the patient.
Items are scored from 0 to 6, yielding a score from 0 to 90.
Higher scores indicate more severe suicidal ideation.
|
Screening, 6 weeks, 24 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Change in suicide related behavior as measured by the Suicide Behavior Questionnaire - Revised
Prazo: Screening, 6 weeks, 24 weeks
|
A 4-item self-report questionnaire that measures suicide behavior, and yields a total score of 3 - 18. Higher scores indicate more severe suicidal behavior.
|
Screening, 6 weeks, 24 weeks
|
Changes in emotional regulation using the Life Problems Inventory
Prazo: Baseline, 6 weeks, 24 weeks
|
A 60-item self-report scale that measures emotional regulation on a 5 point Likert scale from 1 to 5. Higher scores indicate more impaired emotional regulation.
The measure has four subscales: Confusion about Self, Impulsivity, Emotion Dysregulation, and Interpersonal Chaos.
Each subscale has a score from 15 to 75 where a higher score indicates more severity.
|
Baseline, 6 weeks, 24 weeks
|
Change in family conflict as measured by the Conflict Behavior Questionnaire
Prazo: Baseline, 6 weeks, 24 weeks
|
A 20-item scale that examines the parent-child relationship using true/false ratings, yielding a total score of 0 to 20.
Higher scores This measure is completed by both the youth and the parent(s) or caregiver.
Higher scores indicate more severe family conflict.
|
Baseline, 6 weeks, 24 weeks
|
Changes in global impairment as measured by the Columbia Impairment Scale
Prazo: Baseline, 6 weeks, 24 weeks
|
A 13-item scale designed to measure functioning on a 5 point Likert scale from 0 to 4, yielding a total score of 0 to 52.
This measure is completed by both the youth and the parent(s) or caregiver.
Higher scores indicate more severe impairment.
|
Baseline, 6 weeks, 24 weeks
|
Changes in affect regulation as measured by the Children's Affective Lability Scale
Prazo: Baseline, 6 weeks, 24 weeks
|
A 20-item parent-report instrument that measures difficulties with emotion regulation on 5 point Likert scale from 0 to 4, yielding a score from 0 to 80. Higher scores indicate more severe affective lability.
|
Baseline, 6 weeks, 24 weeks
|
Health Care Utilization Survey
Prazo: Baseline, 24 weeks
|
A parent-report qualitative interview of a youth's use of available health care services, medication, and the costs associated with those services.
|
Baseline, 24 weeks
|
Usual Care Tracking Survey
Prazo: Week 1, Week 2, Week 3, Week 4, Week 5, Week 6
|
A parent-report qualitative interview of a youth's use of available health care services over a 1 week period of time.
|
Week 1, Week 2, Week 3, Week 4, Week 5, Week 6
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Daphne J Korczak, MD, MSc, The Hospital for Sick Children
Publicações e links úteis
Publicações Gerais
- Witt KG, Hetrick SE, Rajaram G, Hazell P, Taylor Salisbury TL, Townsend E, Hawton K. Psychosocial interventions for self-harm in adults. Cochrane Database Syst Rev. 2021 Apr 22;4(4):CD013668. doi: 10.1002/14651858.CD013668.pub2.
- Tracey M, Finkelstein Y, Schachter R, Cleverley K, Monga S, Barwick M, Szatmari P, Moretti ME, Willan A, Henderson J, Korczak DJ. Recruitment of adolescents with suicidal ideation in the emergency department: lessons from a randomized controlled pilot trial of a youth suicide prevention intervention. BMC Med Res Methodol. 2020 Sep 14;20(1):231. doi: 10.1186/s12874-020-01117-5.
- Korczak DJ, Finkelstein Y, Barwick M, Chaim G, Cleverley K, Henderson J, Monga S, Moretti ME, Willan A, Szatmari P. A suicide prevention strategy for youth presenting to the emergency department with suicide related behaviour: protocol for a randomized controlled trial. BMC Psychiatry. 2020 Jan 14;20(1):20. doi: 10.1186/s12888-019-2422-y.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 1000056892
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em F-SPS+UC
-
Columbia UniversityConcluído
-
Makerere UniversityUniversity of California, San Francisco; Infectious Diseases Research Collaboration...Desconhecido
-
The Second Affiliated Hospital of Kunming Medical...Concluído
-
Seoul National University HospitalNational Cancer Center, Korea; Seoul National University Bundang Hospital; Seoul... e outros colaboradoresDesconhecidoCâncer retalRepublica da Coréia
-
KU LeuvenRecrutamento
-
Think Now IncorporatedUniversity of California, Berkeley; University of California, Los AngelesRecrutamentoTranstorno de Déficit de Atenção e HiperatividadeEstados Unidos
-
Göteborg UniversityWallström och Sjöbloms stiftelse; Peter Erikssons minnesfond; Back to LifeConcluídoDerrame | Doenças CerebraisSuécia
-
Universidad de ZaragozaConcluídoDor de cabeçaEspanha
-
Stanford UniversityConcluídoCâncer colorretalEstados Unidos
-
Wuhan Union Hospital, ChinaWuhan Hamilton Bio-technology Co., Ltd, China.DesconhecidoCOVID-19 | Pneumonia do novo coronavírus 2019China